

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 12, 13, 17-20, 24-32 and 34-37 are pending in the application, with 12, 34 and 36 being the independent claims. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Based on the above amendment and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

I. *Interview*

Applicants wish to thank the Examiner for the personal interview of October 6, 2004, during which the issue of written descriptive support under 35 U.S.C. §112(1) was discussed. Additionally, Examiner Marschel suggested claim amendments to put the claims into condition for allowance.

II. *Objection to the Specification*

The Examiner has objected to the disclosure because of the following informalities: "1) The Figure 1 Brief Des. cites HBGF-1β whereas, in contrast, Figure 1 cites ECGF." (Paper No. 62904, page 14). Applicants submit herewith formal drawings which omit "ECGF" and eliminates this inconsistency. Thus, Applicants request that the Examiner reconsider and withdraw this objection.

The Examiner has also stated that, "the Figure 2 Brief Des. cites HBGF-1β or HBGF-1, whereas, in contrast, ECGF is cited in Figure 2." The Examiner went on to state that, "within the Figure 2 Brief Des. the growth factor is inconsistently cited as

TNT. SUM. OK
7-11-05
AM